Home Journals Articles Updates About
CN
image
收藏切换
Indirect Efficacy Comparison and Cost-utility Analysis of Enarodustat in the Treatment of Renal Anemia in Patients with Non-Dialysis Chronic Kidney Disease
收藏切换
PDF
Jinsheng GAO, Lei GAN, Ying LIU, Xiaoning HE*
Chinese Pharmaceutical Journal | 2025, 60(2) : 194 - 200
Less
收藏切换
Chinese Pharmaceutical Journal | 2025, 60(2): 194-200
Indirect Efficacy Comparison and Cost-utility Analysis of Enarodustat in the Treatment of Renal Anemia in Patients with Non-Dialysis Chronic Kidney Disease
Full
Jinsheng GAO, Lei GAN, Ying LIU, Xiaoning HE*
Affiliations
  • School of Pharmaceutical Science and Technology, Tianjin University, Tianjin 300072, China
Published: 2025-01-22 doi: 10.11669/cpj.2025.02.013
Outline
收藏切换

OBJECTIVE To evaluate the efficacy and cost-effectiveness of enarodustat in the treatment of renal anemia in non-dialysis patients. METHODS A matched-adjusted indirect comparison of the efficacy of enarodustat and roxadustat was conducted based on their respective phase Ⅲ clinical trials, and the results were used for cost-utility analysis of enarodustat in the treatment of renal anemia in non-dialysis patients. The robustness of the incremental cost-effectiveness ratio was verified through sensitivity analysis and scenario analysis. RESULTS After matching and adjusting the baseline characteristics of the trial population, it was shown that enarodustat was able to significantly increase the proportion of subjects with average hemoglobin ≥10.0 g·dL-1 at weeks 7-9 compared with roxadustat (73.5% vs 61.0%, MD=12.5%, P<0.001); the results of cost-utility analysis showed that compared with roxadustat, enarodustat increased patients' quality-adjusted life years and saved costs, making it an absolutely superior solution.CONCLUSION Compared with roxadustat, enarodustat is more effective and economical in treating renal anemia in patients with non-dialysis chronic kidney disease.

non-dialysis  /  renal anemia  /  enarodustat  /  matching-adjusted indirect comparison  /  cost-utility analysis
Jinsheng GAO, Lei GAN, Ying LIU, Xiaoning HE. Indirect Efficacy Comparison and Cost-utility Analysis of Enarodustat in the Treatment of Renal Anemia in Patients with Non-Dialysis Chronic Kidney Disease[J]. Chinese Pharmaceutical Journal, 2025 , 60 (2) : 194 -200 . DOI: 10.11669/cpj.2025.02.013
Appendix
Less
Year 2025 volume 60 Issue 2
PDF
276
133
Cite this Article
BibTeX
Article Info
doi: 10.11669/cpj.2025.02.013
  • Receive Date：2024-04-02
  • Online Date：2025-11-08
  • Published：2025-01-22
Article Data
Affiliations
History
  • Received：2024-04-02
Affiliations
    School of Pharmaceutical Science and Technology, Tianjin University, Tianjin 300072, China
References
Share
https://castjournals.cast.org.cn/joweb/zgyxzz/EN/10.11669/cpj.2025.02.013
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数
科
Family		 属数
Number of
genus		 种数
Number of
species		 占总种数比例
Percentage of
total species (%)		 属
Genus		 种数
Number of
species		 占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT
Links
Articles
Latest Articles
Most Read
Collections
Updates
Events
News
Multimedia
About
About Us
Contact
No. 86 Xueyuan South Road, Haidian District, Beijing
100081
010-62199257
qkjq@cast.org.cn

Copyright © 2025 China Association for Science and Technology. All rights reserved. For all open access content, the relevant licensing terms apply.
Sponsored by the Office of the Leading Group for Cybersecurity and Informatization of CAST, and supported by Science and Technology Review Publishing House